2,823,178 Shares in Bruker Corporation $BRKR Acquired by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,823,178 shares of the medical research company’s stock, valued at approximately $169,899,000. Bruker makes up about 2.2% of Edmond DE Rothschild Holding S.A.’s investment portfolio, making the stock its 8th largest position. Edmond DE Rothschild Holding S.A. owned 1.85% of Bruker as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Los Angeles Capital Management LLC bought a new stake in Bruker during the 4th quarter worth about $26,000. Allworth Financial LP raised its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the last quarter. Essential Partners LLC acquired a new position in shares of Bruker during the first quarter worth approximately $36,000. Global Retirement Partners LLC acquired a new position in shares of Bruker during the second quarter worth approximately $38,000. Finally, Parallel Advisors LLC grew its stake in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Up 3.1%

Shares of NASDAQ:BRKR opened at $58.65 on Thursday. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30. The company has a 50 day moving average of $58.46 and a 200-day moving average of $47.28. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The stock has a market cap of $8.94 billion, a price-to-earnings ratio of -83.79, a P/E/G ratio of 1.74 and a beta of 1.28.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the business posted $0.32 earnings per share. Bruker’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio is -28.57%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Leerink Partners upped their price objective on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Citigroup lowered their target price on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Bruker has an average rating of “Moderate Buy” and an average price target of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.